Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes
|
Jul 2014
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes
|
Feb 2014
|
Eur J Haematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates
|
Jan 2019
|
Semin Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Detectable mutations precede late myeloid neoplasia in aplastic anemia
|
Feb 2021
|
Haematologica
|
aplastic anemia
|
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po
|
May 2016
|
BMC Hematol
|
myelodysplastic syndromes (MDS)
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes
|
Jun 2016
|
Hematology
|
myelodysplastic syndromes (MDS)
|
Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
|
Jun 2013
|
Immunotherapy
|
myelodysplastic syndromes (MDS)
|